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Summary
Badania immunohistochemiczne w raku tarczycy: czy to ju¿ standard?
Streszczenie
This paper describes results of immunohistochemical studies, used to diagnose primary and metastatic thyroid tumours. We discuss 
differential diagnosis of medullary thyroid carcinoma and c-cell hyperplasia in patients with RET protooncogene mutation, who had 
undergone prophylactic thyroidectomy. In particular, we focus on the possible immunohistochemical differentiation of follicular thyroid 
tumours. We discuss technical issues encountered in applying immunohistochemical methods as well as the commonest errors in the inter-
pretation of results. In conclusion, we indicate areas of thyroid pathology where immunohistochemical staining appears absolutely necessary, 
and others where such methods can merely assist in reaching final diagnostic decision.
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W pracy przedstawiono sposób wykorzystania badañ immunohistochemicznych w diagnostyce guzów pierwotnych i przerzutowych tarczycy. 
Omówiono diagnostykê ró¿nicow¹ raków rdzeniastych tarczycy i rozrostów komórek u chorych z mutacj¹ protoonkogenu RET operowanych 
profilaktycznie. Szczególn¹ uwagê zwrócono na mo¿liwoœci immunohistochemicznego ró¿nicowania guzów tarczycy o budowie pêcherzy-
kowej. Przedstawiono aspekty techniczne immunohistochemii z uwzglêdnieniem przyczyn najczêstszych b³êdów w interpretacji wyników 
reakcji. W podsumowaniu wskazano na dzia³y patologii tarczycy, w których badania immunohistochemiczne s¹ bezwzglêdnie konieczne
oraz te, w których immunohistochemia jest wskazana jako badanie wspomagaj¹ce podjêcie decyzji diagnostycznej.
S³owa kluczowe: tarczyca, immunohistochemia.
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Introduction One of the most important purposes of implementing immu-
nostaining methods is to render histopathologic diagno-
Now histopathologic diagnoses of endocrine glands rank stics more objective and reliable. Until recently, immuno-
among the most difficult since neoplastic processes can histochemistry has not played a major role in differential 
coexist here with functional changes. Diagnostic criteria diagnostics of thyroid cancer, the exception being medu-
applied to microscopic appearance of thyroid disorders llary thyroid carcinoma [3]. 
should include distinguishing parameters, for example, low 
mitotic index and low proliferation activity in cells of diffe- Differential diagnostics of medullary carcinoma
rentiated thyroid cancers or nuclear polymorphism in va-
rious non-malignant disorders of the gland. These criteria Great variability of morphological patterns seen in medu-
result in relatively poor reproducibility of histopathologic llary carcinoma results in a substantial ratio of incorrect 
diagnoses of thyroid disorders [1,2] and become parti- diagnoses. Referral examinations verifying medullary car-
cularly significant upon diagnosis of thyroid malignancies. cinoma cases using immunohistochemistry, carried out
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at the Centre of Oncology in Gliwice between 1993-1995 terial. Evaluation becomes difficult in case of the follicular 
indicated a very high ratio (nearly 33%) of false positive dia- type of papillary carcinoma. The characteristic morpholo-
gnoses [4]. On the other hand, immunostaining verification gical features of cell nuclei, such as grooves and pseudoin-
of atypical, previously diagnosed follicular, anaplastic or pa- clusions can be found in the follicular variant of papillary 
pillary tumours has revealed that they had originated from cancers only in a small number of cells. Typical enlargement 
c-cells. A recommendation adopted at the 1995 Szczyrk of cell nucleus and greater thickness of cell membrane are 
Conference [5] states that each diagnosis of medullar carci- not observed. In uncertain cases encountered in routine 
noma should be confirmed by immunostaining for calci- staining with hematoxylin and eosin the presence of Cytoke-
tonin presence. This procedure becomes indispensable ratin 19 expression in membrane is helpful in reaching can-
in case of RET protooncogene mutation-bearing patients cer diagnosis [16]. Differentiation between follicular and pa-
undergoing prophylactic surgery. It has been often found pillary carcinomas remains, however, a major research is-
that in young patients qualified for surgery on the basis sue. Some carcinomas defined as papillary, owing to their 
of genetic tests the only microscopically observed change nuclear morphology, show nonetheless growth and inva-
involving the thyroid gland is c-cell hyperplasia. Correct sion patterns typical of follicular cancers, with tissue texture 
diagnosis of the malignant growth of c-cells requires preci- containing areas of cells having smaller nuclei and coarse 
sely estimated number of such cells using immunohisto- chromatin pattern characteristic of follicular carcinomas. 
chemistry [6]. The expression of antibodies differentiating between folli-
cular and papillary variants of thyroid cancers, such as cyto-
Immunohistochemistry of follicular tumours of the thy- keratin 5 and 6, cytokeratin 19, galectin-3 and HBME-1 
roid shows heterogeneity which points to the complex nature
of these tumours. This group of carcinomas has been re-
Differential diagnosis of follicular tumours has been a ma- ferred to as hybrid thyroid carcinomas [17]. 
jor challenge for pathologists for many years [7,8]. Micro-
scopic assessment cannot be based here on the morpho- Immunohistochemical staining in poorly differentiated 
logy of cell nucleus seen with H-E staining since in highly and anaplastic carcinomas
differentiated follicular cancers the morphology does not 
essentially differ from that observed for follicular adenomas The degree of differentiation between follicular and pa-
or proliferative thyroid tumours. The sole criteria allowing pillary carcinomas often affects the strategy of chosen 
to differentiate the encapsulated follicular carcinoma variant therapy. Low or negative reaction to the presence of thyreo-
from adenoma are angioinvasion and infiltration of the who- globulin is an indicator of tumour differentiation. It is also
le tumour capsule wall [9]. Such criteria are highly subje- a predictive factor ruling against treatment involving radio-
ctive which results in high ratios (up to 10%) of false positive active iodine. Immunohistochemical diagnostics of poorly 
diagnoses of follicular carcinoma [10,11]. Use of immuno- differentiated cancers, for example insular thyroid cancer, 
histochemical identification of endothelial cells with antibo- poses also technical problems. In this group of cancers 
dies against factor VIII, CD31 or CD34 increases the proba- thyreoglobulin often appears in only trace amounts which 
bility of correctly assessing possible angioinvasion by tu- necessitates use of very sensitive detection methods, strict 
mour cells as well as finding foci of vascular occlusion. adherence to material fixing techniques as well as full stan-
So far, the attempts to use antibodies for differentiating dardisation of subsequent steps in specimens' preparation. 
between benign and malignant follicular lesions have not Cytological features of papillary carcinomas, such as nucle-
been successful. An apparent breakthrough was reported ar grooves and pseudoinclusions, are characteristic also
in 2001 in Lancet [12]. This paper claimed successful cyto- for hyalinising trabecular adenomas. Even though routine 
logical diagnostics of follicular carcinoma based on the ex- cytological examination (FNA) of hyalinising trabecular 
pression of galectin-3 and CD44v6 antigen in tumour cells. adenoma is doomed nowadays to result in false diagnosis 
Subsequent reports have pointed out that the two markers of papillary carcinoma, the examination of tissue material 
should be used along with other antibodies such as cyto- provides, on the other hand, a tool allowing unequivocal 
keratin 19, Hbme-1 and anti-leu-7 [13,14] and that the me- differentiation of this rare benign thyroid tumour. The hyalin-
thod should be considered as supportive only in assess- ising trabecular adenoma features a very characteristic 
ment of controversial cases. Unfortunately, these antibo- expression of Ki-67 membrane antigen [18]. 
dies are expressed to some extent also in benign lesions. 
The group of follicular tumours includes the encapsulated Immunohistochemical diagnostics of metastases
papillary carcinoma variant which involves the highest num- to the thyroid
ber of false positive cancer diagnoses [15]. The classic sub-
type of papillary carcinoma, unambiguously defined based Metastases to the thyroid are relatively common. The pa-
on cell nucleus morphology, does not present a diagnostic thologist's most common dilemma in cases of clear cell 
problem in examining cytological or histopathological ma- tumours with follicular architectonic is whether one faces
a primary clear cell adenoma, or thyroid follicular carci- ex-pression pattern of protein products of p53 (+) and 
noma, or whether is it a metastasis of clear cell kidney carci- p16INK4A (–) suppressor genes [22]. Also, immunohisto-
noma. Until recently differential diagnostics of these entities chemically assessed expression level of telomerase has 
has been mostly based on thyreoglobulin presence in tu- been linked to the aggressiveness of clinical course of pa-
mour cells. One should remember, however, that in some pillary and follicular carcinomas [23]. Despite numerous re-
cases of primary clear cell adenomas and thyroid carci- ports of thyroid cancer potential prognostic factors involving 
nomas immunohistichemical staining reveals very weak expression levels of protooncogenes and suppressor ge-
expression or even absence of thyreoglobulin. At present, nes, current state of knowledge prevents them to be routi-
we have at our disposal a relatively specific TTF-1 antibody nely used in thyroid cancer diagnostics. 
against thyroid transcription factor (TTF) expressed in both 
normal thyreocytes and adenomas, as well as in differen- Conclusions
tiated thyroid carcinomas [19]. By using TTF-1 one can 
differentiate between primary thyroid lesions and metastatic In order to answer the question asked in the title of this 
ones, the only exception being lung adenocarcinoma paper one should concede that immunohistochemical 
metastasis. Its cells also show positive reaction with TTF-1. staining provides a foundation for differential diagnostics
The above antibodies against thyreoglobulin and TTF repre- of medullary, anaplastic and insular thyroid carcinomas
sent also basic markers that confirm distant metastases as well as for thyroid lymphoma; it is also indispensable
to the thyroid. or correctly classifying c-cell proliferation in patients with 
RET protooncogene mutation, who undergo prophylactic 
Interpretation of immunohistochemical staining results surgery. Immunohistochemical studies should form the ba-
and existing problems sis of diagnostics in case of thyroid lymphoma as well
as rare primary tumours of and all metastases to the thyroid. 
Immunohistochemical staining is a very useful tool in di- The method should be supportive in differentiating benign 
fferential diagnostics of cancer diseases. One should bear tumours from follicular thyroid cancers, especially cases
in mind, however, limitations of this method. Papillary carci- of encapsulated variant of follicular papillary carcinoma. 
nomas and oxyphilic thyroid tumours contain large amounts Application of immunohistochemistry in the assessment
of endogenous biotin and this practically obviates the appli- of prognostic factors in thyroid tumours requires further 
cation of methods based on avidin affinity to biotin from dia- studies. 
gnostics of these tumours. Based on our own work (report
in preparation), we are of opinion that immunohistoche-
mical staining, albeit very useful in diagnosing thyroid carci-
nomas, must be used only with the full system of positive Franc B, De La Salmoniere P, Lange F, Hoang C, Louvel A,
and negative control in order to be sure that the staining De Roquancourt A, et al. Interobserver and intraobserver repro-
ducibility m the histopathology of follicular thyroid carcinoma. obtained results indeed from marker presence and its spe-
Hum Pathol 2003;34:1092-100.cific reaction with antibody and not from non-specific tissue 
  2. Lange D, Sporny S, Sygut J, Kula D, Bur³acka J, Jarz¹b M,reaction with visualisation kit reagents. In case of papillary 
et al. Kryteria rozpoznania histopatologicznego raka tarczycycarcinomas and oxyphilic thyroid tumours the assessment 
w szybkim teœcie zgodnoœci. Wiad Lek 2001;54:406-14.is even more difficult since false positive reaction is confined 
  3. Krisch K, Krish I, Hirvat G, Neuhold N, Uirich W. The value
to neoplastic cells only while it is not observed in the vicinity 
of immunohistochemistry in medullary thyroid carcinoma: a sy-
of tumour; this might suggest reaction specificity. It is possi- stematic study of 30 cases. Histopathology 1985;9:1077-89.
ble to avoid such non-specific reactions using polymer   4. Lange D. Rak tarczycy w materiale konsultacyjnym Zak³adu 
based visualisation methods. Patologu Nowotworów Instytutu Onkologii w Gliwicach. Endo-
krynol Pol 1995;46:Supl. 2:63-8.
Immunohistochemical staining in the evaluation of pro-   5. Gembicki M, Jarz¹b B, Królicki L, Kulig A, Ku³akowski A, Lewiñ-
ski A, et al. Rozpoznanie i leczenie raka tarczycy. Rekomenda-gnostic factors in thyroid cancers
cje Komitetu Naukowego Sympozjum "Rak Tarczycy" Nowotwo-
ry 1996;46:250-6.A large number of reports were published recently de-
  6. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus monstrating prognostic significance of assessing expre-
neoplastic c-cell hyperplasia of the thyroid. Separation of dis-ssion products of certain genes. In the context of thyroid 
tinct histologic and biologic entities. Cancer 1996;77:750-6.
cancer metastases, the significance of nm23-H1 protein 
  7. Baloch ZW, Fleisher S, Li Yolsi VA, Gupta PK. Diagnosis of „folli-
expression, a product of suppressor gene bearing the same cular neoplasm": A gray zone in thyroid fine-needle aspiration 
name, has been brought up [20]. Similar role has been cytology. Diagn Cytopathol 2001;26:41-4.
ascribed to the E-cadherin suppressor gene product [21].   8. Baloch ZB, Li Volsi V. The Quest for a magic tumor marker. 
In our own studies we observed a prognostically unfavou- Continuing Saga in Diagnosis of Follicular Lesions of Thyroid. 
rable (distant metastases of follicular thyroid carcinoma) Am J Clin Pathol 2002;118:165-6.
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